Celsion Corp. (CLSN) Chairman Michael H. Tardugno Buys 10,000 Shares

Celsion Corp. (NASDAQ:CLSN) Chairman Michael H. Tardugno bought 10,000 shares of Celsion Corp. stock in a transaction that occurred on Friday, October 7th. The shares were bought at an average cost of $1.14 per share, with a total value of $11,400.00. Following the acquisition, the chairman now directly owns 143,021 shares in the company, valued at approximately $163,043.94. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website.

Shares of Celsion Corp. (NASDAQ:CLSN) traded down 2.56% during mid-day trading on Tuesday, reaching $1.14. 32,713 shares of the company’s stock traded hands. Celsion Corp. has a 12-month low of $1.04 and a 12-month high of $2.31. The company’s market cap is $29.42 million. The firm has a 50-day moving average of $1.23 and a 200 day moving average of $1.34.

Celsion Corp. (NASDAQ:CLSN) last released its quarterly earnings data on Monday, August 15th. The company reported ($0.19) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.21) by $0.02. Celsion Corp. had a negative net margin of 3,966.14% and a negative return on equity of 103.07%. Equities analysts forecast that Celsion Corp. will post ($0.83) EPS for the current year.

Insider Buying and Selling by Quarter for Celsion Corp. (NASDAQ:CLSN)

An institutional investor recently raised its position in Celsion Corp. stock. Sabby Management LLC raised its stake in Celsion Corp. (NASDAQ:CLSN) by 7,986.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,519,365 shares of the company’s stock after buying an additional 1,500,576 shares during the period. Sabby Management LLC owned approximately 6.48% of Celsion Corp. worth $1,930,000 at the end of the most recent reporting period. 15.19% of the stock is owned by institutional investors and hedge funds.

CLSN has been the subject of several research analyst reports. Maxim Group reaffirmed a “buy” rating and set a $4.00 target price on shares of Celsion Corp. in a report on Thursday, September 15th. HC Wainwright reaffirmed a “buy” rating and set a $3.00 target price on shares of Celsion Corp. in a report on Tuesday, July 12th.

Celsion Corp. Company Profile

Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).

5 Day Chart for NASDAQ:CLSN

Receive News & Ratings for Celsion Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion Corp. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.